QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:ICVX

Icosavax (ICVX) Stock Price, News & Analysis

$15.31
0.00 (0.00%)
(As of 02/20/2024)
Today's Range
$15.31
$15.31
50-Day Range
$15.20
$15.58
52-Week Range
$4.75
$16.10
Volume
N/A
Average Volume
1.22 million shs
Market Capitalization
$766.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.50
ICVX stock logo

About Icosavax Stock (NASDAQ:ICVX)

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

ICVX Stock Price History

ICVX Stock News Headlines

Icosavax: Tender Offer With Contingent Value Right
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Icosavax CVR Seems Fairly Valued
Guggenheim Downgrades Icosavax (ICVX)
ICVX Jul 2024 15.000 call
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Icosavax just downgraded at Jefferies, here's why
Icosavax just downgraded at William Blair, here's why
Icosavax initiated with a Buy at Guggenheim
TD Cowen Keeps Their Buy Rating on Icosavax (ICVX)
See More Headlines
Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ICVX
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.50
High Stock Price Target
$28.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+73.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-91,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$580,000.00
Book Value
$5.47 per share

Miscellaneous

Free Float
34,767,000
Market Cap
$766.88 million
Optionable
Optionable
Beta
1.28
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Adam K. Simpson (Age 48)
    President, CEO, Co-Founder & Director
    Comp: $855.95k
  • Mr. Niranjan Kanesa-thasan M.D. (Age 63)
    Chief Medical Officer
    Comp: $641.55k
  • Dr. Cassia Cearley Ph.D. (Age 41)
    Treasurer & Chief Business Officer
    Comp: $632.15k
  • Mr. Neil King Ph.D.
    Chair of Scientific Advisory Board & Co-Founder
  • Dr. David Baker M.D.
    Ph.D., Co-founder & Member of Scientific Advisory Board
  • Mr. Thomas Joseph Russo C.F.A. (Age 52)
    Chief Financial Officer
    Comp: $525.27k
  • Ms. Jennifer Raymond
    Senior Vice President of Technical Operations
  • Ms. Elizabeth Bekiroglu (Age 54)
    General Counsel & Corporate Secretary
    Comp: $230.74k
  • Ms. Lori Stewart
    Senior Vice President of People & Culture
  • Dr. Ami Shah Brown MPH
    Ph.D., Senior Vice President of Regulatory Affairs

ICVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Icosavax stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ICVX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICVX, but not buy additional shares or sell existing shares.
View ICVX analyst ratings
or view top-rated stocks.

What is Icosavax's stock price target for 2024?

3 Wall Street analysts have issued 1-year target prices for Icosavax's stock. Their ICVX share price targets range from $25.00 to $28.00. On average, they predict the company's share price to reach $26.50 in the next year. This suggests a possible upside of 73.1% from the stock's current price.
View analysts price targets for ICVX
or view top-rated stocks among Wall Street analysts.

How have ICVX shares performed in 2024?

Icosavax's stock was trading at $15.76 at the start of the year. Since then, ICVX stock has decreased by 2.9% and is now trading at $15.31.
View the best growth stocks for 2024 here
.

When is Icosavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ICVX earnings forecast
.

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.81. The company had revenue of $1.83 million for the quarter, compared to analyst estimates of $3.30 million.

What ETF holds Icosavax's stock?

Amplify Treatments, Testing and Advancements ETF holds 14,037 shares of ICVX stock, representing 0.78% of its portfolio.

When did Icosavax IPO?

Icosavax (ICVX) raised $150 million in an initial public offering on Thursday, July 29th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

Who are Icosavax's major shareholders?

Icosavax's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.65%), Vanguard Group Inc. (3.65%), Alpine Associates Management Inc. (2.91%), Platinum Investment Management Ltd. (2.76%), Water Island Capital LLC (1.75%) and Segantii Capital Management Ltd (1.03%). Insiders that own company stock include Adam K Simpson, Cassia Cearley, Charles E Richardson, Douglas Holtzman, Elizabeth Bekiroglu, Mark Mcdade, Niranjan Kanesa-Thasan, Ra Capital Management, LP and Thomas Joseph Russo.
View institutional ownership trends
.

How do I buy shares of Icosavax?

Shares of ICVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ICVX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners